<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">helmholtzeyeinstitute</journal-id><journal-title-group><journal-title xml:lang="ru">Российский офтальмологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Ophthalmological Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0076</issn><issn pub-type="epub">2587-5760</issn><publisher><publisher-name>Real time Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21516/2072-0076-2022-15-4-77-83</article-id><article-id custom-type="elpub" pub-id-type="custom">helmholtzeyeinstitute-1102</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Рабдомиосаркома орбиты у детей</article-title><trans-title-group xml:lang="en"><trans-title>Orbital rhabdomyosarcoma in children</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Саакян</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Saakyan</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Светлана Владимировна Саакян — член-корр. РАН, д-р мед. наук, профессор, начальник отдела офтальмоонкологии и радиологии, заведующая учебной частью кафедры глазных болезней</p><p>ул. Садовая-Черногрязская, д. 14/19, Москва, 105062</p><p>ул. Делегатская, д. 20, стр.1, Москва, 127473</p></bio><bio xml:lang="en"><p>Svetlana V. Saakyan — correspondent member of RAS, Dr of Med. Sci., professor, head of ocular oncology and radiology department, deputy director of education, ophthalmology faculty</p><p>14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062</p><p>20/1, Delegatskaya St., Moscow, 127473</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Склярова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sklyarova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Натэлла Владимировна Склярова — канд. мед. наук, научный сотрудник отдела офтальмоонкологии и радиологии</p><p>ул. Садовая-Черногрязская, д. 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>Natella V. Sklyarova — Cand. of Med. Sci., researcher of ocular oncology and radiology department</p><p>14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Цыганков</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Tsygankov</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Александр Юрьевич Цыганков — канд. мед. наук, научный сотрудник отдела офтальмоонкологии и радиологии, ассистент кафедры глазных болезней</p><p>ул. Садовая-Черногрязская, д. 14/19, Москва, 105062</p><p>ул. Делегатская, д. 20, стр.1, Москва, 127473</p></bio><bio xml:lang="en"><p>Alexander Yu. Tsygankov — Cand. of Med. Sci., researcher, ocular oncology and radiology department, assistant at ophthalmology faculty</p><p>14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062</p><p>20/1, Delegatskaya St., Moscow, 127473</p></bio><email xlink:type="simple">alextsygankov1986@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жильцова</surname><given-names>М. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhiltsova</surname><given-names>M. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Марина Георгиевна Жильцова — канд. биол. наук, ведущий научный сотрудник отдела офтальмоонкологии и радиологии</p><p>ул. Садовая-Черногрязская, д. 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>Marina G. Zhiltsova — Cand. of Biol. Sci., senior researcher, ocular oncology and radiology department</p><p>14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алиханова</surname><given-names>В. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Alikhanova</surname><given-names>V. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Валида Рамисовна Алиханова — канд. мед. наук, врач-офтальмолог, заведующий отделением офтальмоонкологии и радиологии</p><p>ул. Садовая-Черногрязская, д. 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>Valida R. Alikhanova — Cand. of Med. Sci., ophthalmologist, ocular oncology and radiology department</p><p>14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тацков</surname><given-names>Р. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tatskov</surname><given-names>R. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Роберт Александрович Тацков — врач-офтальмолог отделения офтальмоонкологии и радиологии</p><p>ул. Садовая-Черногрязская, д. 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>Robert A. Tatskov — ophthalmologist, ocular oncology and radiology department</p><p>14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава России; ФГБОУ ВПО «МГМСУ им. А.И. Евдокимова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Helmholtz National Medical Research Center of Eye Diseases; Yevdokimov Moscow State Medical Stomatological University of Medicine and Dentistry</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Helmholtz National Medical Research Center of Eye Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>14</day><month>12</month><year>2022</year></pub-date><volume>15</volume><issue>4</issue><fpage>77</fpage><lpage>83</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Саакян С.В., Склярова Н.В., Цыганков А.Ю., Жильцова М.Г., Алиханова В.Р., Тацков Р.А., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Саакян С.В., Склярова Н.В., Цыганков А.Ю., Жильцова М.Г., Алиханова В.Р., Тацков Р.А.</copyright-holder><copyright-holder xml:lang="en">Saakyan S.V., Sklyarova N.V., Tsygankov A.Y., Zhiltsova M.G., Alikhanova V.R., Tatskov R.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://roj.igb.ru/jour/article/view/1102">https://roj.igb.ru/jour/article/view/1102</self-uri><abstract><p>Цель исследования — анализ результатов лечения и динамического наблюдения детей с рабдомиосаркомой (РМС) орбиты с учетом витального прогноза. Материал и методы. Обследованы 32 ребенка с РМС (18 мальчиков, 14 девочек) в возрасте от 2 мес до 12 лет. Анамнез заболевания составил от одной до 16 нед (медиана — 5 нед), медиана наблюдения — 60 мес. Опухоль локализовалась в верхнем (n = 13), верхневнутреннем (n = 9), нижнем (n = 4), внутреннем (n = 3) и наружном (n = 3) квадрантах. Проведено первичное хирургическое лечение — орбитотомия с использованием транскутанного (n = 26), трансконъюнктивального (n = 2) и поднадкостничного доступа (n = 4) с последующей цитологической, гистологической и иммуногистохимической верификацией ткани во всех случаях. Результаты. Наибольшее число случаев заболевания отмечено в группе от 2 до 7 лет (66 % пациентов). В стационарных условиях проведено полное макроскопическое удаление РМС в 17 случаях, частичное в 9 случаях, забор биоптата в 6 случаях. РМС эмбрионального типа составила 87 % (n = 28), альвеолярного типа — 13 % (n = 6). Всем детям в послеоперационном периоде проведена комбинированная терапия (системная полихимиотерапия и дистанционная лучевая терапия) в стационарных условиях специализированных онкологических и радиологических клиник. Выживаемость в исследуемой группе детей составила 100 %. В отдаленном периоде (через 3–5 лет) проведены реконструктивные операции по коррекции птоза, косоглазия, очковая или призматическая коррекция сложного или смешанного астигматизма. При развитии синдрома сухого глаза проводили консервативную местную терапию. После экзентерации орбиты применяли эктопротезирование. Заключение. Представлен анализ собственных наблюдений 32 детей с РМС орбиты. Все больные выжили, что свидетельствует о значимости своевременной диагностики и комбинированного лечения опухоли.</p></abstract><trans-abstract xml:lang="en"><p>Purpose. To analyze the results of treatment and active monitoring the children with orbital rhabdomyosarcoma (RMS) with an emphasis on vital prognosis. Material and methods. We examined 32 children with RMS (18 boys, 14 girls) aged 2 months to 12 years, whose case history ranged from 1 week to 16 weeks (median, 5 weeks). The median follow-up was 60 months. The tumor was localized in the upper (n = 13), upper internal (n = 9), lower (n = 4), internal (n = 3), and external (n = 3) quadrants. The patients underwent primary surgical treatment: orbitotomy using transcutaneous (n = 26), transconjunctival (n = 2) and subperiosteal access (n = 4) followed by cytological, histological and immunohistochemical tissue verification in all cases. Results. The highest number of RMS cases was noted in in the 2- to 7-year-old group (66 % of patients). All patients were treated in in-patient settings. Complete macroscopic removal of tumor was performed in 17 cases, partial removal in 9 cases, and biopsy sampling in 6 cases. The embryonic type of RMS accounted for 87 % (n = 28), and the alveolar type, for 13 % (n = 6). In the postoperative period all children received combined therapy (systemic polychemotherapy and distant radiation therapy) in in-patient facilities of special oncological and radiological clinics. The survival rate of the whole group was 100%. In the long-term follow-up period (after 3 to 5 years), reconstructive surgeries were performed to correct ptosis and strabismus, and/or spectacle or prismatic correction of complex or mixed astigmatism. In cases of “dry” eye syndrome, conservative local therapy was offered. After orbital exenteration, ectoprosthesis procedures was applied. Conclusion. The analysis of our observations of 32 children with orbital rhabdomyosarcoma showed a 100 % survival rate, which testifies to the importance of timely diagnosis and combined treatment of the tumor.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рабдомиосаркома орбиты</kwd><kwd>опухоль орбиты</kwd><kwd>выживаемость</kwd><kwd>прогноз</kwd><kwd>лечение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>orbital rhabdomyosarcoma</kwd><kwd>orbital tumor</kwd><kwd>survival rate</kwd><kwd>prognosis</kwd><kwd>treatment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Бровкина А.Ф. Болезни орбиты. Москва: Медицина; 2008.</mixed-citation><mixed-citation xml:lang="en">Brovkina A.F. Orbital diseases. Moscow: Medicina; 2008 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Shields J.A., Shields C.L. Rhabdomyosarcoma: review for the ophthalmologist. Surv. Ophthalmol. 2003; 48: 39–57. doi:10.1016/s0039-6257(02)00415-0</mixed-citation><mixed-citation xml:lang="en">Shields J.A., Shields C.L. Rhabdomyosarcoma: review for the ophthalmologist. Surv. Ophthalmol. 2003; 48: 39–57. doi:10.1016/s0039-6257(02)00415-0</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Turner J.H., Richmon J.D. Head and neck rhabdomyosarcoma: a critical analysis of population-based incidence and survival data. Otolaryngol. Head Neck Surg. 2011; 145: 967–73. doi:10.1177/0194599811417063</mixed-citation><mixed-citation xml:lang="en">Turner J.H., Richmon J.D. Head and neck rhabdomyosarcoma: a critical analysis of population-based incidence and survival data. Otolaryngol. Head Neck Surg. 2011; 145: 967–73. doi:10.1177/0194599811417063</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Conneely M.F., Mafee M.F. Orbital rhabdomyosarcoma and simulating lesions. Neuroimaging Clin. N. Am. 2005; 15: 121–36. doi:10.1016/j.nic.2005.02.006</mixed-citation><mixed-citation xml:lang="en">Conneely M.F., Mafee M.F. Orbital rhabdomyosarcoma and simulating lesions. Neuroimaging Clin. N. Am. 2005; 15: 121–36. doi:10.1016/j.nic.2005.02.006</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Koopman J.H., van der Heiden-van der Loo M., van Dijk M.R., Bijlsma W.R. Incidence of primary malignant orbital tumours in The Netherlands. Eye (Lond) 2011; 25: 461–5. doi:10.1038/eye.2011.9</mixed-citation><mixed-citation xml:lang="en">Koopman J.H., van der Heiden-van der Loo M., van Dijk M.R., Bijlsma W.R. Incidence of primary malignant orbital tumours in The Netherlands. Eye (Lond) 2011; 25: 461–5. doi:10.1038/eye.2011.9</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Karcioglu Z.A., Hadjistilianou D., Rozans M., De Francesco S. Orbital rhabdomyosarcoma. Cancer Control. 2004; 11: 328–3. doi:10.1177/107327480401100507</mixed-citation><mixed-citation xml:lang="en">Karcioglu Z.A., Hadjistilianou D., Rozans M., De Francesco S. Orbital rhabdomyosarcoma. Cancer Control. 2004; 11: 328–3. doi:10.1177/107327480401100507</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Jung A., Bechthold S., Pfluger T., Renner C., Ehrt O. Orbital rhabdomyosarcoma in Noonan syndrome. J. Pediatr. Hematol. Oncol. 2003; 25: 330–2. doi:10.1097/00043426-200304000-00014</mixed-citation><mixed-citation xml:lang="en">Jung A., Bechthold S., Pfluger T., Renner C., Ehrt O. Orbital rhabdomyosarcoma in Noonan syndrome. J. Pediatr. Hematol. Oncol. 2003; 25: 330–2. doi:10.1097/00043426-200304000-00014</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Thavaraj V., Sethi A., Arya L.S. Incomplete Beckwith–Wiedemann syndrome in a child with orbital rhabdomyosarcoma. Indian Pediatr. 2002 Mar; 39: 299–304. PMID: 11910143</mixed-citation><mixed-citation xml:lang="en">Thavaraj V., Sethi A., Arya L.S. Incomplete Beckwith–Wiedemann syndrome in a child with orbital rhabdomyosarcoma. Indian Pediatr. 2002 Mar; 39: 299–304. PMID: 11910143</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Forstner D., Borg M., Saxon B. Orbital rhabdomyosarcoma: multidisciplinary treatment experience. Australas. Radiol. 2006; 50: 41–5. doi:10.1111/j.1440-1673.2005.01526.x</mixed-citation><mixed-citation xml:lang="en">Forstner D., Borg M., Saxon B. Orbital rhabdomyosarcoma: multidisciplinary treatment experience. Australas. Radiol. 2006; 50: 41–5. doi:10.1111/j.1440-1673.2005.01526.x</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Sobel R.K., Ford J.R., Dong W., et al. Frequency and clinical course of residual orbital masses after treatment of orbital rhabdomyosarcoma. Am. J. Ophthalmol. 2021; 234: 28–36. doi:10.1016/j.ajo.2021.06.035</mixed-citation><mixed-citation xml:lang="en">Sobel R.K., Ford J.R., Dong W., et al. Frequency and clinical course of residual orbital masses after treatment of orbital rhabdomyosarcoma. Am. J. Ophthalmol. 2021; 234: 28–36. doi:10.1016/j.ajo.2021.06.035</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Arndt C., Tefft M., Gehan E., et al. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the intergroup rhabdomyosarcoma study (IRS) IV pilot study. J. Pediatr. Hematol. Oncol. 1997; 19: 124–9. doi:10.1097/00043426-199703000-00005</mixed-citation><mixed-citation xml:lang="en">Arndt C., Tefft M., Gehan E., et al. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the intergroup rhabdomyosarcoma study (IRS) IV pilot study. J. Pediatr. Hematol. Oncol. 1997; 19: 124–9. doi:10.1097/00043426-199703000-00005</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Rao A.A., Chen J.Y., Robbins S.L., Ramkumar H.L. A clinical update and radiologic review of pediatric orbital and ocular tumors. J. Oncol. 2013; 2013: 975908. doi:10.1155/2013/975908</mixed-citation><mixed-citation xml:lang="en">Rao A.A., Chen J.Y., Robbins S.L., Ramkumar H.L. A clinical update and radiologic review of pediatric orbital and ocular tumors. J. Oncol. 2013; 2013: 975908. doi:10.1155/2013/975908</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Chung E.M., Smirniotopoulos J.G., Specht C.S., Schroeder J.W., Cube R. From the archives of the AFIP: pediatric orbit tumors and tumorlike lesions: no osseous lesions of the extraocular orbit. Radiographics. 2007; 27: 1777–99. doi:10.1148/rg.276075138</mixed-citation><mixed-citation xml:lang="en">Chung E.M., Smirniotopoulos J.G., Specht C.S., Schroeder J.W., Cube R. From the archives of the AFIP: pediatric orbit tumors and tumorlike lesions: no osseous lesions of the extraocular orbit. Radiographics. 2007; 27: 1777–99. doi:10.1148/rg.276075138</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Breneman J.C., Lyden E., Pappo A.S., et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma – a report from the intergroup rhabdomyosarcoma study IV. J. Clin. Oncol. 2003; 21: 78–84. doi:10.1200/JCO.2003.06.129</mixed-citation><mixed-citation xml:lang="en">Breneman J.C., Lyden E., Pappo A.S., et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma – a report from the intergroup rhabdomyosarcoma study IV. J. Clin. Oncol. 2003; 21: 78–84. doi:10.1200/JCO.2003.06.129</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Chisholm J.C., Marandet J., Rey A., et al. Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J. Clin. Oncol. 2011; 29: 1319–25. doi:10.1200/JCO.2010.32.1984</mixed-citation><mixed-citation xml:lang="en">Chisholm J.C., Marandet J., Rey A., et al. Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J. Clin. Oncol. 2011; 29: 1319–25. doi:10.1200/JCO.2010.32.1984</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mazzoleni S., Bisogno G., Garaventa A., et al. Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Cancer. 2005; 104: 183–90. doi:10.1002/cncr.21138</mixed-citation><mixed-citation xml:lang="en">Mazzoleni S., Bisogno G., Garaventa A., et al. Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma. Cancer. 2005; 104: 183–90. doi:10.1002/cncr.21138</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Yip C.C., Kersten R.C., McCulley T.J., Ballard E.T., Kulwin D.R. Osteogenic sarcoma after orbital radiation rhabdomyosarcoma. Ophthalmology. 2003; 110: 1996–99. doi:10.1016/S0161-6420(03)00478-0</mixed-citation><mixed-citation xml:lang="en">Yip C.C., Kersten R.C., McCulley T.J., Ballard E.T., Kulwin D.R. Osteogenic sarcoma after orbital radiation rhabdomyosarcoma. Ophthalmology. 2003; 110: 1996–99. doi:10.1016/S0161-6420(03)00478-0</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Андреева Л.Д., Хорошилова-Маслова И.П. Иммуноморфология в диагностике рабдомиосаркомы орбиты. Вестник офтальмологии. 2009; 125 (2): 10–3.</mixed-citation><mixed-citation xml:lang="en">Andreeva L.D., Khoroshilova-Maslova I.P. Immunomorphology in orbital rhabdomyosarcoma diagnostics. Vestnik oftal'mologii. 2009; 125 (2): 10–3 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Жильцова М.Г., Вальский В.В., Цыганков А.Ю., Саакян С.В. Опыт цитологической и иммуноцитохимической диагностики рабдомиосаркомы орбиты. Вестник ФГБУ «РОНЦ им. Н.Н. Блохина». 2016; 27 (4): 154–9.</mixed-citation><mixed-citation xml:lang="en">Zhiltsova M.G., Valskiy V.V., Tsygankov A.Yu., Saakyan S.V. Cytological and immunocytochemical diagnostics of orbital rhabdomyosarcoma. Vestnik FGBU “RONC im. N.N. Blokhina”. 2016; 27 (4): 154–9 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Neudorfer M., Leibovitch I., Stolovitch C., et al. Intraorbital and periorbital tumors in children - value of ultrasound and color Doppler imaging in the differential diagnosis. Am. J. Ophthalmol. 2004; 137: 1065–72. doi:10.1016/j.ajo.2004.01.050</mixed-citation><mixed-citation xml:lang="en">Neudorfer M., Leibovitch I., Stolovitch C., et al. Intraorbital and periorbital tumors in children - value of ultrasound and color Doppler imaging in the differential diagnosis. Am. J. Ophthalmol. 2004; 137: 1065–72. doi:10.1016/j.ajo.2004.01.050</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Sohaib S.A., Moseley I., Wright J.E. Orbital rhabdomyosarcoma — the radiological characteristics. Clin. Radiol. 1998; 53: 357–62. doi:10.1016/s0009-9260(98)80009-3</mixed-citation><mixed-citation xml:lang="en">Sohaib S.A., Moseley I., Wright J.E. Orbital rhabdomyosarcoma — the radiological characteristics. Clin. Radiol. 1998; 53: 357–62. doi:10.1016/s0009-9260(98)80009-3</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Andrade C.R., Takahama A., Nishimoto I.N., Kowalski L.P., Lopes M.A. Rhabdomyosarcoma of the head and neck: a clinicopathological and immunohistochemical analysis of 29 cases. Braz. Dent J. 2010; 21: 68–73. doi:10.1590/s0103-64402010000100011</mixed-citation><mixed-citation xml:lang="en">Andrade C.R., Takahama A., Nishimoto I.N., Kowalski L.P., Lopes M.A. Rhabdomyosarcoma of the head and neck: a clinicopathological and immunohistochemical analysis of 29 cases. Braz. Dent J. 2010; 21: 68–73. doi:10.1590/s0103-64402010000100011</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Cintorino M., Vindigni C., Del Vecchio M.T., et al. Expression of actin isoforms and intermediate filament proteins in childhood orbital rhabdomyosarcomas. J. Submicrosc. Cytol. Pathol. 1989; 21: 409–19.</mixed-citation><mixed-citation xml:lang="en">Cintorino M., Vindigni C., Del Vecchio M.T., et al. Expression of actin isoforms and intermediate filament proteins in childhood orbital rhabdomyosarcomas. J. Submicrosc. Cytol. Pathol. 1989; 21: 409–19.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Missiaglia E., Williamson D., Chisholm J., et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J. Clin. Oncol. 2012; 30: 1670–7. doi:10.1200/JCO.2011.38.5591</mixed-citation><mixed-citation xml:lang="en">Missiaglia E., Williamson D., Chisholm J., et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J. Clin. Oncol. 2012; 30: 1670–7. doi:10.1200/JCO.2011.38.5591</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
